Long‐term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study-Reference-Cited by-同舟云学术

Long‐term impact of adalimumab therapy on biomarkers of systemic inflammation in psoriasis: Results of a 2 year study

Published:2020-08-17 Issue:6 Volume:33 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Gkalpakiotis Spyridon¹^ORCID,Arenbergerova Monika¹^ORCID,Gkalpakioti Petra¹,Potockova Jana²,Arenberger Petr¹,Kraml Pavel²

Affiliation:

1. Third Faculty of Medicine, Department of Dermatology and Venereology Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

2. Third Faculty of Medicine, Second Department of Internal Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Funder

Univerzita Karlova v Praze

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.14110

Reference30 articles.

1. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15‐year nationwide population‐based cohort study

2. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions

3. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences